Redwood City, CA – November 21, 2016 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, announced that Jeffrey L. Cleland, PhD, Graybug Vision Chief Executive Officer, will present an update of company research and development on November 29, 2016 at the Piper Jaffray Healthcare Conference in New York City. In April 2016, the company raised $44.5 million in a Series B Financing, in part to fund the Phase 1/2 trial (1H 2017) of its lead product, GB-102, for twice a year treatment of wet AMD patients.
GB-102 consists of an approved receptor tyrosine kinase inhibitor, sunitinib malate, that is known to accumulate at high levels in the eye after oral dosing for cancer without reports of ocular toxicity. Oral dosing however leads to systemic side effects. Graybug Vision has incorporated sunitinib in its novel delivery system to allow a potential twice per year injection, dramatically reducing the current burden of treatment for patients and physicians. In addition, Graybug Vision has advanced its research program on novel glaucoma prodrugs that provide intraocular pressure lowering alone or potentially in combination with neuroprotection from single agents administered to the subconjunctiva twice per year.
Who: Jeffrey L. Cleland, PhD, GrayBug Vision Chief Executive Officer
When: 9:30 am, Tuesday, November 29, 2016
Where: Lotte New York Palace, 455 Madison Avenue, New York City
About Graybug Vision
Graybug Vision is developing novel products for the treatment of people with ocular diseases. The company’s proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases. The company’s lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. Graybug Vision has developed a library of compounds to treat glaucoma by lowering intraocular pressure alone or in combination with neuroprotection when injected twice per year into the subconjunctiva. For more information, please visit www.graybug.com.
– end –